On 10 March 2023 Neuren’s North America partner Acadia Pharmaceuticals received marketing approval from the U.S. Food and Drug Administration (FDA) for DAYBUE™ (trofinetide) to treat Rett syndrome in adults and pediatric patients 2 years of age and older.